Tags : October

Fitbit to Launch ECG App in the US and EU

Shots: Fitbit’s ECG app has received the US FDA’s 510 (k) clearance and EC’s CE marking to assess heart rhythm for atrial fibrillation (AFib). The ECG app will be available in Oct’2020 to the users on the Fitbit Sense smartwatch The company has launched a multi-site clinical trial across the US, to detect AFib from […]Read More

Pfizer and BioNTech Plan for Regulatory Review of its COVID-19

Shots: The companies have shared additional P-I safety and immunogenicity data from their ongoing US study of the BNT162b2 against SARS-CoV-2, which has advanced into P-II/III evaluation. Across all populations, BNT162b2 was well tolerated with mild to moderate fever in fewer than 20% of the participants In P-I study, BNT162b2 (@7days after the second dose […]Read More

Insights+ Key Biosimilars Events of October 2019

Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of the […]Read More

United Healthcare to Prefer Amgen’s Two Anticancer Biosimilars in October

Shots: In Oct’2019 United Healthcare plans utilizing Amgen’s Mvasi (biosimilar, bevacizumab) and Kanjinti (biosimilar, trastuzumab) as preferred products for commercial and community plans (but not Medicare Advantage), while with no longer preference to reference products Avastin and Herceptin   Additionally, on Oct 1, 2019 Sandoz’s Zarxio (biosimilar filgrastim) will be listed as preferred product before […]Read More